Big workers' compensation law firm Pond Lehocky and Philadelphia-area pain doctors make money by steering injured workers to mail-order pharmacies that they own.
Pennsylvania lost 2,900 pharma jobs in the last five years, but there was a net gain because some pharma executives and scientists went to start-ups.
Their drugs combined showed better results for shrinking cancer tumors and preventing progression of advanced melanoma.
After a months-long search, it selected Kare Schultz, an industry veteran who comes from Denmark's H. Lundbeck A/S.
GlaxoSmithKline and Adaptimmune Therapeutics sealed a deal for GSK to develop and commercialize a promising T-cell therapy to treat cancer.
The Center City division of Cardiology Consultants of Philadelphia has moved to Jefferson from the rival University of Pennsylvania Health System.
A Philadelphia Common Pleas Court jury ordered Ethicon, a subsidiary of Johnson & Johnson, to pay damages to a woman left chronically incontinent and in constant pain after receiving a defective pelvic mesh implants.
Public Health Management Corp. has quashed a bid by its subsidiary, the National Nurse-led Care Consortium, to regain its independence.
The federal Centers of Medicare & Medicaid Services on Wednesday published guidance that may allow Center City's Wills Eye Hospital to regain its status as a hospital under Medicare rules, a key to the organization's financial health.
The government of St. Kitts and Nevis has launched an investigation into the clinical trial for a herpes vaccine by an American company because it said its officials were not notified about the experiments.
A federal auditor said Tuesday that Fox Rehabilitation, based in Cherry Hill, received at least $29.9 million from Medicare for services that did not meet Medicare requirements. The services were provided in New Jersey between July 2013 and June 2015.
CSL Behring buys a biotech company with complementary therapies and technologies to treat hemophilia and other disorders.
The health-insurance company sent a letter whose envelope showed customers' names and the names of HIV medications.
Imagine being in the situation some of the nation's CEOs found themselves in last week. Resign from President Trump's manufacturing council? Or stay? What are the consequences either way - for employees, customers, shareholders. What would you do? We asked some local CEOs.